EW · Full Picture

Edwards Lifesciences Corp — the full picture

Earnings window · 2026-07-14 to 2026-08-09 · anchored on the 10-Q report

One earnings window, everything merged: the filing, the call, press releases and news digests, folded into ranked threads.

What to look at first

  1. Revenue Performance and Mix · Revenue growth & mixPriority 77
    +48.3% revenue (realized); 2 sources (news, sec_filing); structured_verified
    Transcatheter Mitral and Tricuspid Therapies (TMTT) net sales for the three months ended June 30, 2026 were $198.6 million, up $64.1 million (47.7%) from $134.5 million in 2025.
  2. Income Tax Rate Changes · TaxPriority 76
    -1.4% net_income; 1 forward row(s); structured_verified
    Edwards recorded a $188.2 million valuation allowance against certain deferred tax assets in Q2 2026 due to enactment of California budget legislation on June 29, 2026.
  3. Geographic Market Commentary · Geographic mixPriority 68
    +15.9% revenue (realized); quote_verified
    Europe net sales for the six months ended June 30, 2026 were $882.2 million, up $162.2 million (22.5%) from $720.0 million in 2025.
  4. Litigation and Legal Risk · Litigation & settlementsPriority 64
    quote_verified
    Certain litigation expenses were $6.3 million and $15.5 million during the three months ended June 30, 2026 and 2025, respectively, and $43.4 million and $26.4 million during the six months ended June 30, 2026 and 2025, respectively.
  5. Liquidity and Debt Position · Debt, leverage & refinancingPriority 60
    quote_verified
    Edwards has a five-year Credit Agreement providing for a $750.0 million unsecured revolving credit facility that matures on July 15, 2027, with an option to increase by up to $250.0 million and extend maturity by one year subject to lender agreement; as of June 30, 2026, no amounts were outstanding under the Credit Agreement.
  6. Tax Litigation and Exposure · Litigation & settlementsPriority 59
    -1.4% liability; 8 forward row(s); structured_verified
    In Q2 2026 Edwards received two draft Notices of Proposed Adjustment that were issued as final prior to the end of the quarter: one proposing an increase to 2018 U.S. taxable income of approximately $233.5 million and another proposing increases to 2018, 2019, and 2020 U.S. taxable income of $625.3 million, $530.7 million, and $683.6 million, respectively.
  7. Capital Return Program · Buybacks & dividendsPriority 56
    -4.0% cash (realized); structured_verified
    During the six months ended June 30, 2026 Edwards repurchased 6.9 million shares at an aggregate cost of $558.7 million, including pursuant to a $500.0 million accelerated share repurchase executed during the period.
  8. Operating Cash Flow and Capex · Capital expenditurePriority 56
    quote_verified
    Net cash flows provided by operating activities were $695.7 million for the six months ended June 30, 2026, an increase of $125.1 million over the same period last year primarily due to lower tax payments.
  9. End-Market Demand Trends · Demand, orders & backlogPriority 50
    qualitative only
  10. VIE Investment Impairment · Restructuring & impairmentPriority 49
    -2.3% operating_income (realized); structured_verified
    In May 2026, Edwards amended agreements with a medical device company (the “Consolidated VIE”) and determined it became the primary beneficiary and consolidated the Consolidated VIE in May 2026.
  11. Acquisition / Partnership / Divestiture · M&A and divestituresPriority 47
    -0.2% liability; 2 forward row(s); structured_verified
    In February 2026, Edwards acquired Autus Valve Technologies, Inc. for total consideration of $128.9 million with contingent consideration of up to $132.5 million payable based on the achievement of certain regulatory and sales milestones.
  12. Regulatory Approval Milestones · Regulatory action & investigationsPriority 42
    4 forward row(s); quote_verified
    In January 2026, Edwards received FDA approval for the SAPIEN 3 transcatheter pulmonic valve delivery system.

Threads by pillar

Revenue & Demand Priority 87 · 4 threads

Costs & Margins Priority 60 · 3 threads

Capital & Balance Sheet Priority 88 · 4 threads

Strategy & Portfolio Priority 47 · 1 thread

Legal, Regulatory & Policy Priority 78 · 4 threads

Guidance & Outlook Priority 30 · 1 thread

Expected impact by metric

metricforward netforward grossrealized
liability-1.6%+1.6%—
net_income-1.4%+1.4%-10.8%
assets+0.2%+0.2%+0.6%
cash——-4.3%
operating_income——-2.3%
revenue——+64.2%